MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO]

Side Effects & Adverse Event Reports


0

Adverse Events

0

Side Effects

2025

Data Starting In

This report has a limited number of adverse event reports which may not fully reflect the safety profile of this product. It's important to understand that:

  • Only manufacturers are required to report adverse events — for everyone else, reporting is voluntary.
  • It's estimated that only about 10% of adverse events are ever reported.
  • Some people may not realize their experience qualifies as an adverse event.
  • Others may assume someone else has already reported the issue.
  • A lack of awareness about how and where to report can also reduce submissions.
Your report can help close this gap. Whether your experience was mild or serious, sharing it contributes to a fuller understanding of product safety and can help others make better health decisions.

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO].

Understanding the potential Side Effects and Adverse Events of MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO] is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO] may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO] are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO]?

    SymPedia shows MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO] adverse event reports for 0.

  • How many side effects have been reported for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO]?

    SymPedia shows MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO] side effect reports for 0.

  • What year does the MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO] reporting data start?

    SymPedia reporting data on this page starts in 2025.

  • What years are included in the yearly chart for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML [BEXSERO]?

    SymPedia yearly chart data is not available for this page.

  • Is adverse event reporting mandatory?

    SymPedia notes that only manufacturers are required to report adverse events. For other reporters, submission is generally voluntary, which can lead to underreporting.

MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE

Side Effects & Adverse Event Reports


0

Adverse Events

0

Side Effects

2025

Data Starting In

This report has a limited number of adverse event reports which may not fully reflect the safety profile of this product. It's important to understand that:

  • Only manufacturers are required to report adverse events — for everyone else, reporting is voluntary.
  • It's estimated that only about 10% of adverse events are ever reported.
  • Some people may not realize their experience qualifies as an adverse event.
  • Others may assume someone else has already reported the issue.
  • A lack of awareness about how and where to report can also reduce submissions.
Your report can help close this gap. Whether your experience was mild or serious, sharing it contributes to a fuller understanding of product safety and can help others make better health decisions.

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE.

Understanding the potential Side Effects and Adverse Events of MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE?

    SymPedia shows MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE adverse event reports for 0.

  • How many side effects have been reported for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE?

    SymPedia shows MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE side effect reports for 0.

  • What year does the MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE reporting data start?

    SymPedia reporting data on this page starts in 2025.

  • What years are included in the yearly chart for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE?

    SymPedia yearly chart data is not available for this page.

  • Is adverse event reporting mandatory?

    SymPedia notes that only manufacturers are required to report adverse events. For other reporters, submission is generally voluntary, which can lead to underreporting.

MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO]

Side Effects & Adverse Event Reports


0

Adverse Events

0

Side Effects

2025

Data Starting In

This report has a limited number of adverse event reports which may not fully reflect the safety profile of this product. It's important to understand that:

  • Only manufacturers are required to report adverse events — for everyone else, reporting is voluntary.
  • It's estimated that only about 10% of adverse events are ever reported.
  • Some people may not realize their experience qualifies as an adverse event.
  • Others may assume someone else has already reported the issue.
  • A lack of awareness about how and where to report can also reduce submissions.
Your report can help close this gap. Whether your experience was mild or serious, sharing it contributes to a fuller understanding of product safety and can help others make better health decisions.

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO].

Understanding the potential Side Effects and Adverse Events of MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO] is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO] may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO] are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO]?

    SymPedia shows MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO] adverse event reports for 0.

  • How many side effects have been reported for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO]?

    SymPedia shows MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO] side effect reports for 0.

  • What year does the MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO] reporting data start?

    SymPedia reporting data on this page starts in 2025.

  • What years are included in the yearly chart for MENINGOCOCCAL GROUP B VACCINE 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT FHBP FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B RECOMBINANT NHBA FUSION PROTEIN ANTIGEN 0.1 MG/ML / NEISSERIA MENINGITIDIS SEROGROUP B STRAIN NZ98/254 OUTER MEMBRANE VESICLE 0.05 MG/ML PREFILLED SYRINGE [BEXSERO]?

    SymPedia yearly chart data is not available for this page.

  • Is adverse event reporting mandatory?

    SymPedia notes that only manufacturers are required to report adverse events. For other reporters, submission is generally voluntary, which can lead to underreporting.